Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Merck KGaA
  6. Summary
    MRK   DE0006599905

MERCK KGAA

(MRK)
  Report
Delayed Quote. Delayed Xetra - 12/03 11:35:14 am
213.6 EUR   +0.52%
12/03MARKETMIND : Omicron and payrolls (TGIF)
RE
12/02MARKETMIND : Vol takes a toll
RE
12/01MARKETMIND : Transitory, you are toast
RE
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
11/29/2021 11/30/2021 12/01/2021 12/02/2021 12/03/2021 Date
219.6(c) 218.9(c) 216.3(c) 212.5(c) 213.6(c) Last
412 218 700 142 463 384 472 670 432 649 Volume
-1.52% -0.32% -1.19% -1.76% +0.52% Change
More quotes
Estimated financial data (e)
Sales 2021 19 600 M 22 173 M 22 173 M
Net income 2021 2 958 M 3 346 M 3 346 M
Net Debt 2021 9 051 M 10 239 M 10 239 M
P/E ratio 2021 31,2x
Yield 2021 0,73%
Sales 2022 20 977 M 23 731 M 23 731 M
Net income 2022 3 233 M 3 658 M 3 658 M
Net Debt 2022 6 881 M 7 784 M 7 784 M
P/E ratio 2022 28,5x
Yield 2022 0,79%
Capitalization 92 869 M 105 B 105 B
EV / Sales 2021 5,20x
EV / Sales 2022 4,76x
Nbr of Employees 59 308
Free-Float 29,7%
More Financials
Company
Merck KGaA is a Germany-based science and technology company. The Company operates in three business segments: Healthcare, Life Sciences and Performance Materials. The Healthcare business, which operates in the United States and Canada as EMD Serono, focuses on such therapeutic areas as allergies, fertility, oncology and neurodegenerative diseases, developing drugs, diagnostic substances and medical devices. The... 
Sector
Pharmaceuticals
Calendar
03/03 | 01:00amEarnings Release
More about the company
Ratings of Merck KGaA
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
A-
More Ratings
All news about MERCK KGAA
12/03MARKETMIND : Omicron and payrolls (TGIF)
RE
12/02MARKETMIND : Vol takes a toll
RE
12/01MARKETMIND : Transitory, you are toast
RE
11/30EMD Serono Launches New Fertility LifeLines Portal to Increase Support and Access for P..
AQ
11/26MERCK - 54% of Europeans consider their current physical health to be good or very good..
AQ
11/25MERCK KGAA : Gets a Buy rating from Barclays
MD
11/24MARKETMIND : Brace for it
RE
11/23MARKETMIND : Mind the (Europe-U.S.) gap
RE
11/22MERCK KGAA : Goldman Sachs remains a Sell rating
MD
11/18Advanz Pharma Names New CEO, CFO
MT
11/17Merck KGaA and Burning Rock Collaborate on Liquid-biopsy Based CDx Development Using Bu..
CI
11/17Pfizer Strikes Supply Deal With Merck KGaA, Imugene for Clinical Trial of Gastric Cance..
MT
11/17Pfizer Strikes Supply Agreement With Imugene, Merck KGaA for Clinical Trial of Gastric ..
MT
11/17Smile on dollar bulls
RE
11/17Imugene Announces Clinical Trial Supply Agreement with Merck Kgaa, Darmstadt, Germany a..
CI
More news
News in other languages on MERCK KGAA
11/29KORREKTUR : XETRA-SCHLUSS/DAX nach Ausverkauf mit Mini-Erholung
11/29XETRA-SCHLUSS/DAX nach Ausverkauf mit Mini-Erholung
11/26AKTIEN FRANKFURT SCHLUSS : Virusvariante schickt Dax auf Talfahrt
11/25MERCK KGAA : Barclays reste à surpondérer
11/25OPINIONES DE LOS ANALISTAS DEL DÍA : Melia Hotels, Scandic, Enel, Merck, Tryg, Accord, Val..
More news
Analyst Recommendations on MERCK KGAA
More recommendations
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MRK | DE0006599905 | MarketScreener
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 213,60 €
Average target price 211,23 €
Spread / Average Target -1,11%
EPS Revisions
Managers and Directors
Belén Garijo López Chairman-Executive Board & CEO
Marcus Kuhnert Chief Financial Officer
Wolfgang Heinz Büchele Chairman-Supervisory Board
Maria Rivas Chief Medical Officer & Senior Vice President
Laura Matz Chief Science & Technology Officer
Sector and Competitors